Lipid Peroxidation and Total Cholesterol in HAART-Naïve Patients Infected with Circulating Recombinant Forms of Human Immunodeficiency Virus Type-1 in Cameroon

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Teto, Georges ^a   Kanmogne, Georgette D ^c   Torimiro, Judith N ^a,b   Alemnji, George ^a   Nguemaim, Flore N ^a   Takou, Désiré ^b   Nanfack, Aubin ^b   Tazoacha, Asonganyi ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Chantal Biya International Reference Centre (CIRCB)   (Cameroon)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE;

ADULT; ARTICLE; CAMEROON; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CIRCULATING RECOMBINANT FORM; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATIENT MONITORING; SEQUENCE ANALYSIS; VIRUS FORMS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMEROON; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEMOGRAPHY; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; PHYLOGENY; RECOMBINATION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878749541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065126     Document Type: Article

References (46)

1. Levy JA, (2007) HIV and the pathogenesis of AIDS. American society for microbiology 3: 87-88.
2. UNAIDS (2011): Journée mondiale sida/2011. Rapport ONUSIDA.
3. UNAIDS (2010) Rapport ONUSIDA sur l'épidemie mondiale de sida.
4. National AIDS Control Committee/National Statistique Institute (2006) Preliminary Report of Cameroon Demographic and Health survey 2005.
5. Plantier JC, Leoz Marie, Dickerson EJ, Oliveira De Fabienne, Cordonnier francois, et al. (2009)A new human immunodeficiency virus derived from gorillas. Nature medicine; Brief communication:1-2. Available: http://www. nature. com/naturemedecine/. Accessed 12 May 2012.
6. Heyndrickx L, Janssens W, Ndumbe P, Vereecken K, Coppens S, et al. (2000) HIV-1 genetic variability in Cameroon. Research Letters: 1862-1864.
7. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, et al. (2000) HIV-1 nomenclature proposal. A reference guide to HIV-1 classification. Science 288: 55-65.
8. Agwale SM, Robbins KE, Odama L, Saekou A, Zeh C, et al. (2001) Development of an env gp 41-based heteroduplex mobility assay for rapid human immunodeficiency virus type 1 subtyping. J Clin Microbiol 39: 2110-2114.
9. HIV sequence data base (2012) Available: www. Hiv. lanl. Gov/content/sequence/hiv/cirfs/cirfs. Html ≠ crf16.5. Accessed 28 July 2012.
10. Adje C, Cheingsong R, Roels HT, Maurice C, Djomand G, et al. (2001) High prevalence of genotypic and phenotypic HIV-1 drug-resistance strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr 26: 501-506.
11. Heyndrickx L, Auwera GV (2002). Heteroduplex mobility analysis, une technique de mobilité électrophorétique des hétéroduplexes. kit, version 5.
12. Marston B, (2004) Multivitamins, nutrition, and antiretroviral therapy for HIV disease in Africa. New England Journal of Medicine 351: 78-80.
13. Suresh DR, Vamseedhar Annam, Pratibha K, Maruti Prasad BV, (2009) Total antioxidant capacity - a novel early bio-chemical marker of oxidative stress in HIV infected individuals. Journal of Biomedical Science 16: 16-61.
14. Hamsten A, (1990) Hypertriglyceridemia, triglyceride rich lipoproteins and coronary heart disease. In Betteridge J Ed. Lipid and Lipoprotein disorders. London. Baillière Tindall International practice and research series 4: 895-922.
15. Nguemaïm NF, Mbuagbaw J, Nkoa T, Alemnji G, Teto G, et al. (2010) Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case control study. HIV Medicine 11: 353-359.
16. Fulbert JC, Cals MJ, (1992) Les radicaux libres en biologie clinique: origine, rôle pathogène et moyen de défense. Path Biol 40: 66-67.
17. Halliwell B, Cross CE, (1991) Reactive oxygen species, antioxidants, and acquired immunodeficiency syndrome. Arch Intern Med 151: 29-31.
18. Jerri L, Lemorre Mc, Peggy Beeley, Karla Thorton, Kevin Morrisroe, et al. (1997) Rapid automated determination of lipid hydroperoxide concentrations and total antioxidant status of serum samples from patients infected with HIV. Am J Clin Pathol 109: 268-273.
19. Clement B, Ndongmo, Danuta Pieniazek, Mona Holberg-Petersen, Carol Holm-Hansen, et al. (2006) HIV genetic diversity in Cameroon: possible public health importance. AIDS Research and Human Retroviruses 22(8): 812-816.
20. Ndembi N, Takehisa J, Zekeng L, Kobayashi E, Ngansop Ch, et al. (2004) Genetic Diversity of HIV Type 1 in Rural Eastern Cameroon. JAIDS 37: 1641-1650.
21. Benzie Iris FF, Strain JJ, (1996) The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power assay. Anal. Biochem 239: 70-76.
22. Kohn HI, Liversedge M, (1944) On a New Aerobic Metabolite Whose Production by Brain Is Inhibited by Apomorphine, Methine, Ergotamine, Epinephrine and Menadione. J Pharm Exp Therap 83: 292-300.
23. Lefevre G, Beljean-Leymarie M, Beyerle F, Bonnefont-Rousselot D, Cristol JP, et al. (1998) Evaluation de la peroxydation lipidique par le dosage des substances réagissant avec l'acide thiobarbiturique. Ann Biol Clin 56: 305-319.
24. Friedewald WT, Levy RI, Lees RS, (1972) Estimation of concentration of low density lipoprotein cholesterol in plasma, without use the preparative ultracentrifuge. Clin Chem 18: 499-502.
25. Thomson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
26. Saitou N, Nei M, (1987) The neighbour joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-425.
27. Felsenstein J, (1985) Confidence limits on phylogenies: an approach using the bootstrap. Evolution 36: 783-791.
28. Kimura M, (1980) A simple method for estimating evolutionary rate of base substitution through comparative studies of nucleotides sequences. J Mol Evol 16: 111-120.
29. Belec L (1993) Thérapeutique pratique du SIDA. Médecine. 9-40.
30. Hinninger I-Favier (2011). Les lipides et dérivés. Cours de biochimie. Available: www.médiatrice-grenoble.fr. Accessed 20 June 2012.
31. Ariel C (1997) Cardiologie et pathologie vasculaire. Editions Scientifiques, Techniques et Médicales. 1113 p.
32. Martin Zabell (2011) Normal Cholesterol Levels by Age. Available: http://www.livestrong.com/article/275091-normal-cholesterol-levels-by-age/. Accessed 23 August 2012.
33. Raisonnier A, Tagny JP, Kamso-Tchakounté J, Sile HJ, Muna W, (1988) Apolipoprotein and lipid composition of low-density lipoproteins and high-density lipoproteins in Cameroonians: A very low atherogenic risk. Ann.Univ.Sc.Santé 5(3-4): 755-763.
34. Nguemaïm NF, Mbuagbaw J, Teto G, Nkoa T, Samé-Ekobo A, et al. (2012) Morphological Changes in HIV-1 Infected Patients on Antiretroviral Therapy without Protease Inhibitors in Cameroon: A Prospective Cohort Study. J.Med.Sci 12(5): 131-1.
35. Safrin S, Grunfeld C, (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13: 2493-505.
36. Fawzi W-W, (2004) A randomized trial of multivitamin supplements and HIV disease progression and mortality. New England Journal of Medicine 351: 23-32.
37. Suraiya Rasheed, Jasper SY, Alex Lau, Arvan S, (2008) Chan (2008) HIV Replication Enhances Production of Free Fatty Acids, Low Density Lipoproteins and Many Key Proteins Involved in Lipid Metabolism: A Proteomics Study. Open access 3: 1-15.
38. Rabaud Ch, Tronel H, Fremont S, May T, Canton P, et al. (1997) Radicaux libres et infection par le VIH. Annales de Biologie Clinique 55(6): 565-71.
39. Lopez O, Bonnefont-Rousselot D, Mollereau M, (1996) Increased plasma thiobarbituric acid-reactive substances (TBARS) before opportunistic infection symptoms in HIV infected individuals. Clin Chim Acta 247: 181-187.
40. L'Hénaff M (2006) Stress oxydatif et VIH: Les antioxydants qui dérouillent. Journal du sida n°188. Available: http://www. webmestrearcat-sante.org. Accessed 08 July 2012.
41. Djinhi J, Tiahou G, Zirihi G, Lohoues E, Monde A, et al. (2008) Déficit en sélénium et stress oxidant chez les personnes infectées par le VIH1 cliniquement asymptomatiques en Côte d'Ivoire. Biologie clinique n° 3279: 11-13.
42. Montagnier L (2003). Apports de la recherche dans la lutte contre le Sida en Afrique. 5 décembre 2003; Rapport.
43. Ducobu J, et Payen M, (2000) Lipides et SIDA. Rev Méd Brux 1: 11-7.
44. Chaix M, Delaugerre C, Ghosn J, (2007) Les sous-types du VIH-1: épidémiologie et impact. Lett Infect 22(2): 56-60.
45. Falutz Julian, Potvin Diane, Mamputu Jean-Claude, Assaad Hani, Zoltowska Monika, et al. (2010) "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomised placebo-controlled trial with a safety extension". J Acquir Immune Defic Syndr: advance online publication.
46. Belec L (2007) Transmission sexuelle de l'infection par le VIH. John Libbey Eurotext 301-309.